Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.04.16.001255v1?rss=1 Authors: Marks, D., Heinen, N., Bachmann, L., Meermeyer, S., Werner, M., Gallego Vilarejo, L., Nolte, S., Hemmerich, P., Bader, V., Winklhofer, K., Schroeder, E., Knauer, S., Mueller, T. Abstract: The amyloid precursor protein (APP) is a type I transmembrane protein with unknown physiological function. The current study demonstrates that APP signals to the nucleus causing the generation of aggregates comprising its adapter protein FE65 and the tumour suppressor proteins p53 and PML. The PML nuclear body generation, known to be of relevance in virus defence and cell division, is induced and fusion occurs over time depending on APP signalling. We further show that the nuclear aggregates of APP C-terminal (APP-CT) fragments together with PML and FE65 are present in the aged human brain but not in cerebral organoids differentiated from iPS cells. Notably, human Alzheimer's disease brains reveal a highly significant loss of these nuclear aggregates in areas with high plaque load compared to plaque-free areas of the same individual. Based on these results we conclude that APP-CT signalling to the nucleus takes place in the aged human brain and is potentially involved in the pathophysiology of AD. Taken the current knowledge on PML bodies into account, we hypothesize a new role for APP as a twofold virus response protein. The APP-dependent defence strategy includes A{beta}-virus interaction at the extracellular matrix and APP-CT driven PML aggregation in the nucleus to encapsulate the viral nucleic acid. This defence strategy preferentially occurs in high-plaque regions of the human brain and overstimulation of this pathway results in a pyrrhic victory. Copy rights belong to original authors. Visit the link for more info